ATE469159T1 - Substituierte oxadiazaspiro-ä5.5ü- undecanonderivate und ihre verwendung als neurokininantagonisten - Google Patents
Substituierte oxadiazaspiro-ä5.5ü- undecanonderivate und ihre verwendung als neurokininantagonistenInfo
- Publication number
- ATE469159T1 ATE469159T1 AT06708618T AT06708618T ATE469159T1 AT E469159 T1 ATE469159 T1 AT E469159T1 AT 06708618 T AT06708618 T AT 06708618T AT 06708618 T AT06708618 T AT 06708618T AT E469159 T1 ATE469159 T1 AT E469159T1
- Authority
- AT
- Austria
- Prior art keywords
- antagonistic activity
- combined
- undecanone
- derivatives
- pain
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- KYWIYKKSMDLRDC-UHFFFAOYSA-N undecan-2-one Chemical class CCCCCCCCCC(C)=O KYWIYKKSMDLRDC-UHFFFAOYSA-N 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 abstract 5
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 2
- VSEBMUIKMRMUON-UHFFFAOYSA-N 2-oxa-3,4-diazaspiro[5.5]undecan-1-one Chemical class O=C1ONNCC11CCCCC1 VSEBMUIKMRMUON-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000021891 Micturition disease Diseases 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000027288 circadian rhythm Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 201000011461 pre-eclampsia Diseases 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000020341 sensory perception of pain Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 230000009278 visceral effect Effects 0.000 abstract 1
- 208000009935 visceral pain Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nanotechnology (AREA)
- Pulmonology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05101657 | 2005-03-03 | ||
| PCT/EP2006/060419 WO2006094934A1 (en) | 2005-03-03 | 2006-03-03 | Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE469159T1 true ATE469159T1 (de) | 2010-06-15 |
Family
ID=34938877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06708618T ATE469159T1 (de) | 2005-03-03 | 2006-03-03 | Substituierte oxadiazaspiro-ä5.5ü- undecanonderivate und ihre verwendung als neurokininantagonisten |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8138334B2 (de) |
| EP (1) | EP1874783B1 (de) |
| JP (1) | JP5094422B2 (de) |
| KR (1) | KR101355064B1 (de) |
| CN (1) | CN101133064B (de) |
| AT (1) | ATE469159T1 (de) |
| AU (1) | AU2006222061B2 (de) |
| BR (1) | BRPI0608074A2 (de) |
| CA (1) | CA2598530C (de) |
| DE (1) | DE602006014531D1 (de) |
| EA (1) | EA012421B1 (de) |
| ES (1) | ES2346147T3 (de) |
| MX (1) | MX2007010728A (de) |
| NZ (1) | NZ556629A (de) |
| WO (1) | WO2006094934A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| CN102762572A (zh) | 2010-02-01 | 2012-10-31 | 诺瓦提斯公司 | 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物 |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
| EP3915560A1 (de) | 2014-06-25 | 2021-12-01 | Emory University | Verfahren zur bewältigung von bedingter angst mit neurokinin-rezeptor-antagonisten |
| KR101579688B1 (ko) | 2014-07-08 | 2015-12-24 | 재단법인 전남생물산업진흥원 | 좁쌀풀 추출물을 유효성분으로 함유하는 과민성 대장증후군에 의한 내장 통증 억제예방 또는 치료용 약학 조성물 |
| US11458129B2 (en) | 2017-11-02 | 2022-10-04 | California Institute Of Technology | Neurokinin antagonists and uses thereof |
| WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
| WO2020048828A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds |
| WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
| WO2022020209A1 (en) * | 2020-07-18 | 2022-01-27 | Hoth Therapeutics, Inc. | Compositions and methods for treating lung inflammation |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5403593A (en) * | 1991-03-04 | 1995-04-04 | Sandoz Ltd. | Melt granulated compositions for preparing sustained release dosage forms |
| GB9109862D0 (en) | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
| TW429256B (en) | 1995-12-27 | 2001-04-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives |
| TW531537B (en) * | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
| TW382017B (en) | 1995-12-27 | 2000-02-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives |
| AU9540898A (en) | 1997-08-29 | 1999-03-22 | Dsm N.V. | Granules free of excipients |
| US6482829B2 (en) * | 2000-06-08 | 2002-11-19 | Hoffmann-La Roche Inc. | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor |
| DE60140708D1 (de) | 2000-08-10 | 2010-01-14 | Mitsubishi Tanabe Pharma Corp | Prolinderivative und deren Verwendung als Medikamente |
| DE60227657D1 (de) * | 2001-05-14 | 2008-08-28 | Hoffmann La Roche | 1-OXA-3,9-DIAZASPIROc5.5ÜUNDECAN-2-ONDERIVATE UND ZEPTORS |
| NZ571695A (en) * | 2001-12-28 | 2010-02-26 | Acadia Pharm Inc | Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events |
| MY141736A (en) * | 2002-10-08 | 2010-06-15 | Elanco Animal Health Ireland | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists |
| CA2527856A1 (en) * | 2003-06-10 | 2004-12-23 | Janssen Pharmaceutica N.V. | Substituted 1, 4-di-piperidin-4-yl-piperazine derivative combined with an opioid analgesic and their use for the treatment of pain and side-effects associated with opioid-based treatments |
| JP2007522160A (ja) * | 2004-02-10 | 2007-08-09 | エフ．ホフマン−ラ ロシュ アーゲー | ケモカインｃｃｒ５受容体モジュレーター |
-
2006
- 2006-03-03 AT AT06708618T patent/ATE469159T1/de not_active IP Right Cessation
- 2006-03-03 AU AU2006222061A patent/AU2006222061B2/en not_active Ceased
- 2006-03-03 DE DE602006014531T patent/DE602006014531D1/de not_active Expired - Lifetime
- 2006-03-03 NZ NZ556629A patent/NZ556629A/en not_active IP Right Cessation
- 2006-03-03 MX MX2007010728A patent/MX2007010728A/es active IP Right Grant
- 2006-03-03 CA CA2598530A patent/CA2598530C/en not_active Expired - Fee Related
- 2006-03-03 ES ES06708618T patent/ES2346147T3/es not_active Expired - Lifetime
- 2006-03-03 JP JP2007557517A patent/JP5094422B2/ja not_active Expired - Fee Related
- 2006-03-03 KR KR1020077020930A patent/KR101355064B1/ko not_active Expired - Fee Related
- 2006-03-03 EP EP06708618A patent/EP1874783B1/de not_active Expired - Lifetime
- 2006-03-03 EA EA200701879A patent/EA012421B1/ru not_active IP Right Cessation
- 2006-03-03 CN CN2006800066125A patent/CN101133064B/zh not_active Expired - Fee Related
- 2006-03-03 US US11/913,890 patent/US8138334B2/en not_active Expired - Fee Related
- 2006-03-03 WO PCT/EP2006/060419 patent/WO2006094934A1/en not_active Ceased
- 2006-03-03 BR BRPI0608074-0A patent/BRPI0608074A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2346147T3 (es) | 2010-10-11 |
| NZ556629A (en) | 2010-04-30 |
| JP2008531659A (ja) | 2008-08-14 |
| US8138334B2 (en) | 2012-03-20 |
| US20100292228A1 (en) | 2010-11-18 |
| WO2006094934A8 (en) | 2006-12-07 |
| DE602006014531D1 (de) | 2010-07-08 |
| CA2598530C (en) | 2014-12-16 |
| AU2006222061B2 (en) | 2011-04-28 |
| EA012421B1 (ru) | 2009-10-30 |
| EA200701879A1 (ru) | 2008-02-28 |
| WO2006094934A1 (en) | 2006-09-14 |
| CN101133064A (zh) | 2008-02-27 |
| CA2598530A1 (en) | 2006-09-14 |
| JP5094422B2 (ja) | 2012-12-12 |
| MX2007010728A (es) | 2007-10-12 |
| CN101133064B (zh) | 2011-02-23 |
| EP1874783A1 (de) | 2008-01-09 |
| KR20070113224A (ko) | 2007-11-28 |
| BRPI0608074A2 (pt) | 2009-11-03 |
| EP1874783B1 (de) | 2010-05-26 |
| KR101355064B1 (ko) | 2014-01-24 |
| AU2006222061A1 (en) | 2006-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200604198A (en) | Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists | |
| JO2527B1 (en) | Derivatives of second-aza-Spiro- (5,5) -andecan and their use as antihistamines | |
| TW200603797A (en) | Substituted 4-alkyl- and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists | |
| TW200700068A (en) | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | |
| TNSN08104A1 (en) | Pyrimidine amide compounds as pgds inhibitors | |
| WO2008080844A9 (en) | Azaspiro derivatives | |
| WO2004056799A3 (en) | Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | |
| NZ561747A (en) | (Pyrrol-2-ylmethyl)-indol-1-yl-acetic acid derivatives with PGD2 antagonist activity | |
| ATE469159T1 (de) | Substituierte oxadiazaspiro-ä5.5ü- undecanonderivate und ihre verwendung als neurokininantagonisten | |
| EA200601868A1 (ru) | 3- или 4-монозамещённые производные фенола и тиофенола, полезные в качестве н-лигандов | |
| MX2009005507A (es) | Derivados de espiro-piperidina. | |
| NO20082297L (no) | Piperazinderivater som er anvendelige som CCR5-antagonister | |
| MX2009006454A (es) | Derivados de espiro-piperidina. | |
| MX2009005541A (es) | Indoles que actuan como antagonistas del receptor v1a. | |
| DE602007004327D1 (de) | Einen azepin-kern enthaltende antagonisten des histaminrezeptors | |
| ATE478075T1 (de) | Diazaspiro-ä4,4ü-nonanderivate als neurokinin- (nk1)-antagonisten | |
| WO2006011024A3 (en) | New tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | |
| MX2009005504A (es) | Derivados de espiro piperidina como antagonistas del receptor via. | |
| MX2009006446A (es) | Derivados de espiro-piperidina. | |
| EA200801342A1 (ru) | 3-(4-{[4-(4-{[3-(3,3-диметил-1-пиперидинил)пропил]окси}фенил)-1-пиперидинил]карбонил}-1-нафталинил)пропановая или пропеновая кислота в качестве антагонистов н1 и н3-рецепторов для лечения воспалительных и аллергических расстройств | |
| TW200700390A (en) | Metabolites for nk-1 antagonists for emesis | |
| MY145168A (en) | Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists | |
| ATE438620T1 (de) | Azetidin-derivate als ccr-3-rezeptor-antagonisten | |
| TH103173A (th) | อนุพันธ์ของไดอะซา-สปิโร-[5.5]-อันเดคเคนและการใช้ของมันเป็นแอนทาโกนิสท์ของนิวโรไคนิน | |
| TH82341A (th) | อนุพันธ์ของไดอะซา-สปิโร-[4.5]-เดคเคนและการใช้ของมันเป็นแอนทาโกนิสท์ของนิวโรไคนิน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |